Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1434-9949
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years ; volume:33 ; number:10 ; day:2 ; month:2 ; year:2014 ; pages:1433-1441 ; date:10.2014
Clinical rheumatology ; 33, Heft 10 (2.2.2014), 1433-1441, 10.2014
- Creator
-
Kingsbury, Daniel J.
Bader-Meunier, Brigitte
Patel, Gina
Arora, Vipin
Kalabic, Jasmina
Kupper, Hartmut
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10067-014-2498-1
- URN
-
urn:nbn:de:101:1-2019102209020199344128
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kingsbury, Daniel J.
- Bader-Meunier, Brigitte
- Patel, Gina
- Arora, Vipin
- Kalabic, Jasmina
- Kupper, Hartmut
- SpringerLink (Online service)
Other Objects (12)
Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan
Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data
Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
Adalimumab-induced manic episode in an adolescent with juvenile idiopathic arthritis
Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
Efficacy of adalimumab in refractory juvenile idiopathic arthritis related uveitis: report of 6 cases
Juvenile idiopathische Arthritis – Adalimumab – sicher und effizient
Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
Adalimumab Effectively Decreases Inflammation Downstream of TNFα Signaling in Synoviocytes from Extended Oligoarticular Juvenile Idiopathic Arthritis
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan
Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data
Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
Adalimumab-induced manic episode in an adolescent with juvenile idiopathic arthritis
Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
Efficacy of adalimumab in refractory juvenile idiopathic arthritis related uveitis: report of 6 cases
Juvenile idiopathische Arthritis – Adalimumab – sicher und effizient
Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
Adalimumab Effectively Decreases Inflammation Downstream of TNFα Signaling in Synoviocytes from Extended Oligoarticular Juvenile Idiopathic Arthritis
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan
Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data
Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
Adalimumab-induced manic episode in an adolescent with juvenile idiopathic arthritis
Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
Efficacy of adalimumab in refractory juvenile idiopathic arthritis related uveitis: report of 6 cases
Juvenile idiopathische Arthritis – Adalimumab – sicher und effizient
Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
Adalimumab Effectively Decreases Inflammation Downstream of TNFα Signaling in Synoviocytes from Extended Oligoarticular Juvenile Idiopathic Arthritis